Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

Mostrar otras versiones (1)

BACKGROUND: RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Rha, S. Y., Flaig, T. W., Page, R. D., Beck, J. T., Cheung, F., Yadav, S., Patel, P., Geoffrois, L., Niolat, J., Berkowitz, N., Marker, M., Chen, D., Motzer, R. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452072/
https://www.ncbi.nlm.nih.gov/pubmed/28327953
http://dx.doi.org/10.1093/annonc/mdx075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452072/
https://www.ncbi.nlm.nih.gov/pubmed/28327953
http://dx.doi.org/10.1093/annonc/mdx075

Ejemplares similares